Developing the next generation of gene editing therapeutics

 

 

cas9_purple_with_box.png

PLATFORM

Our Active Cas Targeting platform yields gene editing nucleases which are targeted to specific cell populations

swirll_complex_320_240_e.png

DISEASE FOCUS

 We are actively developing therapeutics targeting tumors by harnessing the addressable molecules generated by our platform

people_dummy-smaller-still.png

PEOPLE

Our team of immunologists, oncologists, protein engineers and gene editors is working to develop and advance our preclinical pipeline